Celgene's Revenue in the fiscal year 2018 $ 15,281.00 millions
Celgene's Revenue in the fiscal year 2017 $ 13,003.00 millions
Celgene's Revenue in the fiscal year 2016 $ 11,229.20 millions
Celgene's Revenue in the fiscal year 2015 $ 9,256.00 millions
Celgene's Revenue in the fiscal year 2014 $ 7,670.40 millions
CELG Revenue third quarter 2019 Y/Y Growth Comment
Celgene Corp reported Revenue increase of 16.14% year on year in the third quarter 2019, to $ 4,520.00 millions, this is lower than Celgene Corp's recent average Revenue improvement of 30.14%.
Looking into third quarter 2019 results within Major Pharmaceutical Preparations industry 111 other companies have achieved higher Revenue growth. While Celgene Corp' s Revenue growth of 16.14% ranks overall at the positon no. 1173 in the third quarter 2019.
Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019
Celgene's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
29.63 %
6.81 %
-11.12 %
(June 30. 2005)
CELG's III. Quarter Q/Q Revenue Comment
Celgene Corp achieved in the III. Quarter 2019 below company average Revenue growth of 2.73% quarter on quarter, to $ 4,520.00 millions.
III. Quarter 2019 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 2.05% in the III. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 118 other companies have achieved higher Revenue quarter on quarter growth. While Celgene's Revenue growth quarter on quarter, overall rank is 1678.
Celgene Corp achieved in the III. Quarter 2019 below company average Revenue growth of 2.73% quarter on quarter, to $ 4,520.00 millions.
III. Quarter 2019 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 2.05% in the III. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 118 other companies have achieved higher Revenue quarter on quarter growth. While Celgene's Revenue growth quarter on quarter, overall rank is 1678.
Celgene's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Sep 30 2019)
12 Months Ending (Jun 30 2019)
12 Months Ending (Mar 31 2019)
12 Months Ending (Dec 31 2018)
12 Months Ending (Sep 30 2018)
Cumulative Revenue 12 Months Ending
$ 16,982.00
$ 16,354.00
$ 15,768.00
$ 15,281.00
$ 14,727.00
Y / Y Revenue Growth (TTM)
15.31 %
15.81 %
16.15 %
17.56 %
17.86 %
Year on Year Revenue Growth Overall
Ranking
# 908
# 1019
# 1013
# 0
# 1022
Seqeuential Revenue Change (TTM)
3.84 %
3.72 %
3.19 %
3.76 %
4.28 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 1885
# 1024
# 1005
# 1007
# 1159
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2019 period, Celgene's cumulative twelve months Revenue were $ 16,982 millions, company would post below average annual Revenue growth of 4.28% year on year, if the fiscal year would end at Sep 30 2019. A slow-down in the Celgene's Revenue growth from the 4400% growth in Jun 30 2019.
In the Healthcare sector 191 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 908, from total ranking in previous quarter at 1019.
With the quarterly Revenue reported in the Sep 30 2019 period, Celgene's cumulative twelve months Revenue were $ 16,982 millions, company would post below average annual Revenue growth of 13.73% year on year, if the fiscal year would end at Sep 30 2019. A slow-down in the Celgene's Revenue growth from the 4400% growth in Jun 30 2019.
In the Healthcare sector 191 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 908, from total ranking in previous quarter at 1019.
About Celgene Revenue Growth Rates (CELG), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
27.37%